welcome
Insider

Insider

Health

Health

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

Insider
Summary
Nutrition label

82% Informative

Hims & Hers' revenue grew by 69% in 2024 , with GLP-1 drugs representing about 15% of sales.

Last week , the FDA removed semaglutide, the active ingredient in Ozempic , from its shortage list.

The FDA allows for the sale of compounded versions of drugs on the shortage list to limit patient supply issues.

VR Score

86

Informative language

87

Neutral language

51

Article tone

semi-formal

Language

English

Language complexity

40

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links